Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Rho GTPases play important roles in cytoskeleton organization, cell cycle progression and are key regulators of tumor progression. Strategies to modulate increased Rho GTPase activities during cancer progression could have therapeutic potential. Methods: We report here the characterization of a Cdc42-selective small-molecule inhibitor AZA197 for the treatment of colon cancer that was developed based on structural information known from previously developed compounds affecting Rho GTPase activation. We investigated the effects of AZA197 treatment on RhoA, Rac1 and Cdc42 activities and associated molecular mechanisms in colon cancer cells in vitro. Therapeutic effects of AZA197 were examined in vivo using a xenograft mouse model of SW620 human colon cancer cells. After treatment, tumors were excised and processed for Ki-67 staining, TUNEL assays and Western blotting to evaluate proliferative and apoptotic effects induced by AZA197. Results: In SW620 and HT-29 human colon cancer cells, AZA197 demonstrated selectivity for Cdc42 without inhibition of Rac1 or RhoA GTPases from the same family. AZA197 suppressed colon cancer cell proliferation, cell migration and invasion and increased apoptosis associated with down-regulation of the PAK1 and ERK signaling pathways in vitro. Furthermore, systemic AZA197 treatment reduced tumor growth in vivo and significantly increased mouse survival in SW620 tumor xenografts. Ki-67 staining and tissue TUNEL assays showed that both inhibition of cell proliferation and induction of apoptosis associated with reduced PAK/ERK activation contributed to the AZA197-induced therapeutic effects in vivo. Conclusions: These data indicate the therapeutic potential of the small-molecule inhibitor AZA197 based on targeting Cdc42 GTPase activity to modulate colorectal cancer growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · cited 17×
“Thus it is possible, that compound screening of modifications of a known inhibitor, such as with the Rac1-GEF inhibitor NSC23766 presented here, can result in the identification of an inhibitor that could affect the activation status of another RhoGTPase which was not predicted by mechanistic in silico analysis of bin…”
InfluentialEbi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases
(2008) · Methods in Enzymology · doi:10.1016/s0076-6879(07)00409-0 · Cited by 126 · cited 1×
“A number of inhibitors either targeting Rho GTPase activity directly [1,5] or targeting regulators of Rho GTPase activity (e.”
Cited by
Targeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 237
“AZA197 Dbs/Cdc42 1–10 mmol/L (36) (36) (36)”
BackgroundTargeting Rac and Cdc42 GEFs in Metastatic Cancer
Maldonado, M. D. M., Medina, J. I., Velazquez, L., & Dharmawardhane, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00201 · Cited by 122
Pharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases
Guiler, W., Koehler, A., Boykin, C., & Lu, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661612 · Cited by 51
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
Jahid, S., Ortega, J. A., Vuong, L. M., Acquistapace, I. M., Hachey, S. J., Flesher, J. L., La Serra, M. A., Brindani, N., La Sala, G., Manigrasso, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110641 · Cited by 21
Metadata
- Authors
- Zins, K., Gunawardhana, S., Lucas, T., Abraham, D., & Aharinejad, S.
- Venue
- Journal of Translational Medicine
- Published
- 2013-11-27
- Volume
- 11
- Issue
- 1
- Pages
- 295-295
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2107760762
- Cited by
- 68
- References
- 3
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity. https://app.cochat.ai/papers/10.1186/1479-5876-11-295
- The paper
- Zins, K., Gunawardhana, S., Lucas, T., Abraham, D., & Aharinejad, S. (2013). Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.